Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 146 participants.
Also called NCT02695277
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 146 participants
- Sponsor
- Registry
-
NCT02695277
-
- Other papers using this trial's data
- Durable effectiveness and safety of hybrid ablation versus catheter ablation: 2-year results from the randomized CEASE-AF trial†
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Czechia, Germany, Netherlands, Poland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02695277. Randomized; no masking; primary purpose treatment. Start 2015-11 (actual); primary completion 2022-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation
- Acronym
- CEASE-AF
- Condition
- Atrial Fibrillation
- Condition
- Persistent and Longstanding Persistent Atrial Fibrillation
- Intervention (Device)
- AtriCure Bipolar System
- Intervention (Device)
- Standard Endocardial Ablation with Catheter
- Intervention (Device)
- AtriClip® PRO LAA Exclusion System
- Intervention (Device)
- Endocardial Ablation with Catheter
- Intervention (Device)
- Repeated Endocardial ablation(s)
- Lead sponsor
- AtriCure, Inc.
- Collaborator
- Cardialysis BV
Record details
- Record id
cardio:ct-nct02695277- Content hash
17f228b764f6f45bb0507bad28ef8b8e9e4cd5b489139c36343bfd67a09cef09